Decreased cerebral cortical serotonin transporter binding in ecstasy users: A positron emission tomography/[11C]DASB and structural brain imaging study

Brain

Volumn 133, Issue 6, 2010, Pages 1779-1797

  Kish, Stephen J ^a   Lerch, Jason ^b   Furukawa, Yoshiaki ^a,c   Tong, Junchao ^a   McCluskey, Tina ^a   Wilkins, Diana ^d   Houle, Sylvain ^a   Meyer, Jeffrey ^a   Mundo, Emanuela ^e   Wilson, Alan A ^a   Rusjan, Pablo M ^a   Saint Cyr, Jean A ^a   Guttman, Mark ^a,f   Collins, D Louis ^g   Shapiro, Colin ^h   Warsh, Jerry J ^a   Boileau, Isabelle ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c JUNTENDO TOKYO KOTO GERIATRIC MEDICAL CENTER   (Japan)

^d UNIVERSITY OF UTAH   (United States)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f Centre for Movement Disorders   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Cortical thickness; Ecstasy; MDMA; Methamphetamine; PET; Serotonin transporter

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CARBON 11 N,N DIMETHYL 2 (2 AMINO 4 CYANOPHENYLTHIO) BENZYLAMINE; ESTRADIOL; FOLLITROPIN; RADIOISOTOPE; SEROTONIN TRANSPORTER; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HIPPOCAMPUS; HUMAN; INSULA; MALE; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL;

ADULT; AMPHETAMINE-RELATED DISORDERS; BENZYLAMINES; BRAIN; CARBON RADIOISOTOPES; CEREBRAL CORTEX; CHRONIC DISEASE; FEMALE; HALLUCINOGENS; HORMONES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SLEEP;

EID: 77952985523     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq103     Document Type: Article

References (116)

1. Ad-Dab'bagh Y, Einarson D, Lyttelton O, Muehlboeck JS, Mok K, Ivanov O, et al. The CIVET image-processing environment: a fully automated comprehensive pipeline for anatomical neuroimaging research. In: NeuroImage, editor. Organization for Human Brain Mapping. Italy: Florence; 2006.
2. Ad-Dab'bagh Y, Singh V, Robbins S, Lerch J, Lyttelton O, Fombonne E, et al. Native space cortical thickness measurement and the absence of correlation to cerebral volume. In: Zilles K, editor. Organization for human brain mapping. Toronto, Canada: Neuroimage; 2005.
3. Bailey DL, Young H, Bloomfield PM, Meikle SR, Glass D, Myers MJ, et al. ECAT ART\a continuously rotating PET camera: performance characteristics, initial clinical studies, and installation considerations in a nuclear medicine department. Eur J Nucl Med 1997; 24: 6-15.
4. Boileau I, Guttman M, Rusjan P, Adams JR, Houle S, Tong J, et al. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. Brain 2009; 132: 1366-1375
5. Bouso JC, Doblin R, Farre M, Alcazar MA, Gomez-Jarabo G. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J Psychoactive Drugs 2008; 40: 225-236
6. Buchert R, Thiele F, Thomasius R, Wilke F, Petersen K, Brenner W, et al. Ecstasy-induced reduction of the availability of the brain serotonin transporter as revealed by [11C](+)McN5652-PET and the multi-linear reference tissue model: loss of transporters or artifact of tracer kinetic modelling? J Psychopharmacol 2007; 21: 628-634
7. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, et al. Long-term effects of "ecstasy" use on serotonin transporters of the brain investigated by PET. J Nucl Med 2003; 44: 375-384
8. Buchert R, Thomasius R, Petersen K, Wilke F, Obrocki J, Nebeling B, et al. Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users. Eur J Nucl Med Mol Imaging 2006; 33: 188-199
9. Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, et al. A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. Am J Psychiatry 2004; 161: 1181-1189
10. Chakravarty MM, Sadikot AF, Germann J, Bertrand G, Collins DL. Towards a validation of atlas warping techniques. Med Image Anal 2008; 12: 713-726
11. Chang L, Cloak C, Patterson K, Grob C, Miller EN, Ernst T. Enlarged striatum in abstinent methamphetamine abusers: a possible compensatory response. Biol Psychiatry 2005; 57: 967-974
12. Chung MK, Taylor J. Diffusion smoothing on brain surface via finite element method, biomedical imaging: macro to nano. IEEE Int Symp 2004; 1: 432-435
13. Cohen RS. Subjective reports on the effects of the MDMA ('ecstasy') experience in humans. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 1137-1145
14. Collins Dl HC. Automatic 3D model-based neuroanatomical segmentation. Hum Brain Mapp 1995; 3: 190.
15. Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr 1994; 18: 192.
16. Cook EH Jr, Courchesne R, Lord C, Cox NJ, Yan S, Lincoln A, et al. Evidence of linkage between the serotonin transporter and autistic disorder. Mol Psychiatry 1997; 2: 247-250
17. Cowan RL, Lyoo IK, Sung SM, Ahn KH, Kim MJ, Hwang J, et al. Reduced cortical gray matter density in human MDMA (Ecstasy) users: a voxel-based morphometry study. Drug Alcohol Depend 2003; 72: 225-235
18. Cselenyi Z, Olsson H, Farde L, Gulyas B. Wavelet-aided parametric mapping of cerebral dopamine D2 receptors using the high affinity PET radioligand [11C]FLB 457. Neuroimage 2002; 17: 47-60.
19. Cselenyi Z, Olsson H, Halldin C, Gulyas B, Farde L. A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [11C]FLB 457 and [11C]WAY 100635. Neuroimage 2006; 32: 1690-1708
20. Davidson C, Gow AJ, Lee TH, Ellinwood EH. Methamphetamine neuro-toxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 2001; 36: 1-22.
21. de Sola Llopis S, Miguelez-Pan M, Pena-Casanova J, Poudevida S, Farre M, Pacifici R, et al. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study. J Psychopharmacol 2008; 22: 498-510.
22. de Win MM, Jager G, Booij J, Reneman L, Schilt T, Lavini C, et al. Sustained effects of ecstasy on the human brain: a prospective neu-roimaging study in novel users. Brain 2008a; 131: 2936-2945
23. de Win MM, Jager G, Booij J, Reneman L, Schilt T, Lavini C, et al. Neurotoxic effects of ecstasy on the thalamus. Br J Psychiatry 2008b; 193: 289-296
24. Defrise M, Kinahan PE, Townsend DW, Michel C, Sibomana M, Newport DF. Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imaging 1997; 16: 145-158
25. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test-II. San Antonio, TX, 2000.
26. Denman SB. Denman Neuropsychology Memory Scale: Norms, 1987.
27. Dumont GJ, Verkes RJ. A review of acute effects of 3,4-methylenediox- ymethamphetamine in healthy volunteers. J Psychopharmacol 2006; 20: 176-187
28. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale, in Recent development in Parkinson's disease. Vol.2. Macmillan Healthcare Information, 1987.
29. First MB, Spitzer RL, Gibbon M, Williams JW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders-Non-patient Edition (SCID-I/NP, 11/2002 revision). New York: New York State Psychiatric Institute; 2002.
30. Frankle WG, Huang Y, Hwang DR, Talbot PS, Slifstein M, Van Heertum R, et al. Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. J Nucl Med 2004; 45: 682-694
31. Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S. Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab 2001; 21: 1342-1353
32. Goldstein RZ, Craig AD, Bechara A, Garavan H, Childress AR, Paulus MP, et al. The neurocircuitry of impaired insight in drug addiction. Trends Cogn Sci 2009; 13: 372-380
33. Gough B, Ali SF, Slikker W Jr, Holson RR. Acute effects of 3,4-methy-lenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol Biochem Behav 1991; 39: 619-623
34. Gronwall DM. Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills 1977; 44: 367-373
35. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
36. Hartley AA, Speer NK. Locating and fractionating working memory using functional neuroimaging: storage, maintenance, and executive functions. Microsc Res Tech 2000; 51: 45-53.
37. Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4- methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 1999; 19: 5096-5107
38. Hedlund JL, Vieweg BW. The Hamilton ratting scale for depression. J Operat Psychiatry 1979; 10: 149-165
39. Hekmatpanah CR, Peroutka SJ. 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylene- dioxymethamphetamine and related agents. Eur J Pharmacol 1990; 177: 95-98
40. Hoppe CD, Muller UD, Werheid KD, Thone AD, von Cramon YD. Digit Ordering Test: clinical, psychometric, and experimental evaluation of a verbal working memory test. Clin Neuropsychol 2000; 14: 38-55.
41. Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, et al. Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 2003; 23: 1096-1112
42. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-1539
43. Jernigan TL, Gamst AC, Archibald SL, Fennema-Notestine C, Mindt MR, Marcotte TD, et al. Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry 2005; 162: 1461-1472
44. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-545
45. Kalasinsky KS, Hugel J, Kish SJ. Use of MDA (the "love drug") and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA). J Forensic Sci 2004; 49: 1106-1112
46. Kalbitzer J, Frokjaer VG, Erritzoe D, Svarer C, Cumming P, Nielsen FA, et al. The personality trait openness is related to cerebral 5-HTT levels. Neuroimage 2009; 45: 280-285
47. Kim JS, Singh V, Lee JK, Lerch J, Ad-Dab'bagh Y, MacDonald D, et al. Automated 3-D extraction and evaluation of the inner and outer cortical surfaces using a Laplacian map and partial volume effect classification. Neuroimage 2005; 27: 210-221
48. Kish S, Fitzmaurice P, Chang L, Furukawa Y, Tong J. Low striatal serotonin transporter protein in a human polydrug MDMA (ecstasy) user: a case study. J Psychopharmacol 2010; 24: 281-284
49. Kish SJ. How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacol Biochem Behav 2002; 71: 845-855
50. Kish SJ, Fitzmaurice PS, Boileau I, Schmunk GA, Ang LC, Furukawa Y, et al. Brain serotonin transporter in human methamphetamine users. Psychopharmacology (Berl) 2009; 202: 649-661
51. Kish SJ, Furukawa Y, Chang LJ, Tong J, Ginovart N, Wilson A, et al. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nucl Med Biol 2005; 32: 123-128
52. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-1123
53. Lerch JP, Evans AC. Cortical thickness analysis examined through power analysis and a population simulation. Neuroimage 2005; 24: 163-173
54. Lerch JP, Pruessner JC, Zijdenbos A, Hampel H, Teipel SJ, Evans AC. Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cereb Cortex 2005; 15: 995-1001.
55. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-1531
56. Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 2000; 22: 513-521
57. Liechti ME, Vollenweider FX. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylene- dioxymethamphetamine ('Ecstasy') in healthy volunteers. J Psychopharmacol 2000; 14: 269-274
58. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990; 10: 740-747
59. Lu NZ, Eshleman AJ, Janowsky A, Bethea CL. Ovarian steroid regulation of serotonin reuptake transporter (SERT) binding, distribution, and function in female macaques. Mol Psychiatry 2003; 8: 353-360
60. Lyttelton O, Boucher M, Robbins S, Evans A. An unbiased iterative group registration template for cortical surface analysis. Neuroimage 2007; 34: 1535-1544
61. MacDonald D, Kabani N, Avis D, Evans AC. Automated 3-D extraction of inner and outer surfaces of cerebral cortex from MRI. Neuroimage 2000; 12: 340-356
62. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003; 23: 285.
63. Mash DC, Staley JK, Izenwasser S, Basile M, Ruttenber AJ. Serotonin transporters upregulate with chronic cocaine use. J Chem Neuroanat 2000; 20: 271-280
64. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001; 21: 1034.
65. Mazziotta J, Toga A, Evans A, Fox P, Lancaster J, Zilles K, et al. A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM). Philos Trans R Soc Lond B Biol Sci 2001; 356: 1293-1322
66. McCann UD, Ricaurte GA. Amphetamine neurotoxicity: accomplishments and remaining challenges. Neurosci Biobehav Rev 2004; 27: 821-826
67. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 1998a; 352: 1433-1437
68. McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, et al. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology 2005; 30: 1741-1750
69. McCann UD, Szabo Z, Vranesic M, Palermo M, Mathews WB, Ravert HT, et al. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methyle-nedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology (Berl) 2008; 200: 439-450
70. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 1998b; 18: 8417-8422
71. Mendelsohn D, Riedel WJ, Sambeth A. Effects of acute tryptophan depletion on memory, attention and executive functions: a systematic review. Neurosci Biobehav Rev 2009; 33: 926-952
72. Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, Ginovart N, et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 2004; 61: 1271-1279
73. Nelson HE. National Adult Reading Test (NART). NFER-Nelson: Windsor; 1982.
74. Parrott AC. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 2002; 71: 837-844
75. Parrott AC. Chronic tolerance to recreational MDMA (3,4-methylene- dioxymethamphetamine) or Ecstasy. J Psychopharmacol 2005; 19: 71-83.
76. Parrott AC, Lock J, Conner AC, Kissling C, Thome J. Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: prospective neu-roendocrine and psychobiological changes. Neuropsychobiology 2008; 57: 165-180
77. Parrott AC, Marsden CA. MDMA (3,4-methylenedioxymethampheta-mine) or ecstasy: the contemporary human and animal research perspective. J Psychopharmacol 2006; 20: 143-146
78. Parsey RV, Hastings RS, Oquendo MA, Hu X, Goldman D, Huang YY, et al. Effect of a triallelic functional polymorphism of the serotonin-transporter- linked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry 2006; 163: 48-51.
79. Peterson BS, Warner V, Bansal R, Zhu H, Hao X, Liu J, et al. Cortical thinning in persons at increased familial risk for major depression. Proc Natl Acad Sci USA 2009; 106: 6273-6278
80. Praschak-Rieder N, Kennedy J, Wilson AA, Hussey D, Boovariwala A, Willeit M, et al. Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [(11)C] DASB positron emission tomography study. Biol Psychiatry 2007; 62: 327-331
81. Praschak-Rieder N, Willeit M, Wilson AA, Houle S, Meyer JH. Seasonal variation in human brain serotonin transporter binding. Arch Gen Psychiatry 2008; 65: 1072-1078
82. Ramamoorthy S, Blakely RD. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 1999; 285: 763-766
83. Rehavi M, Sepcuti H, Weizman A. Upregulation of imipramine binding and serotonin uptake by estradiol in female rat brain. Brain Res 1987; 410: 135-139
84. Reimold M, Smolka MN, Schumann G, Zimmer A, Wrase J, Mann K, et al. Midbrain serotonin transporter binding potential measured with [11C]DASB is affected by serotonin transporter genotype. J Neural Transm 2007; 114: 635-639
85. Reitan RM. Validity of the trail making test as an indicator organic brain damage. Perceptual and Motor Skills 1958; 8: 271-276
86. Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB, et al. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 2001; 358: 1864-1869.
87. Renoir T, Paizanis E, Yacoubi ME, Saurini F, Hanoun N, Melfort M, et al. Differential long-term effects of MDMA on the serotoninergic system and hippocampal cell proliferation in 5-HTT knock-out vs. wild-type mice. Int J Neuropsychopharmacol 2008; 11: 1149-1162
88. Ricaurte GA, McCann UD. Experimental studies on 3,4-methylenediox- ymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neurons. Neurotox Res 2001; 3: 85-99.
89. Robbins S, Evans AC, Collins DL, Whitesides S. Tuning and comparing spatial normalization methods. Med Image Anal 2004; 8: 311-323
90. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med 1998; 39: 904.
91. Rudnick G, Wall SC. The molecular mechanism of "ecstasy" [3,4-methy-lenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA 1992; 89: 1817-1821.
92. Rush AJ, Carmody T, Reimitz PE. The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. International Journal of Methods in Psychiatric Research 2000; 9: 45-59.
93. Rusjan P, Mamo D, Ginovart N, Hussey D, Vitcu I, Yasuno F, et al. An automated method for the extraction of regional data from PET images. Psychiatry Res 2006; 147: 79-89.
94. Scheffel U, Szabo Z, Mathews WB, Finley PA, Dannals RF, Ravert HT, et al. In vivo detection of short-and long-term MDMA neurotoxicity-a positron emission tomography study in the living baboon brain. Synapse 1998; 29: 183-192
95. Schmidt CJ, Levin JA, Lovenberg W. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminer-gic systems in the rat brain. Biochem Pharmacol 1987; 36: 747-755
96. Schmidt CJ, Wu L, Lovenberg W. Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. Eur J Pharmacol 1986; 124: 175-178
97. Selvaraj S, Hoshi R, Bhagwagar Z, Murthy NV, Hinz R, Cowen P, et al. Brain serotonin transporter binding in former users of MDMA ('ecstasy'). Br J Psychiatry 2009; 194: 355-359
98. Shapiro CM, Auch C, Reimer M, Kayumov L, Heslegrave R, Huterer N, et al. A new approach to the construct of alertness. J Psychosom Res 2006; 60: 595-603.
99. Shopsin B, Friedman E, Gershon S. Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch Gen Psychiatry 1976; 33: 811-819
100. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998; 17: 87.
101. Smith A. Symbol Digits Modalities Test. Western Psychological Services, Los Angeles, 1982.
102. Smith SM. Fast robust automated brain extraction. Human Brain Mapp 2002; 17: 143-155
103. Sowell ER, Peterson BS, Kan E, Woods RP, Yoshii J, Bansal R, et al. Sex differences in cortical thickness mapped in 176 healthy individuals between 7 and 87 years of age. Cereb Cortex 2007; 17: 1550-1560
104. Spreen O, Strauss E. A compendium of neuropsychological tests. 2nd edn., New York: Oxford University Press; 1998.
105. Stone DM, Stahl DC, Hanson GR, Gibb JW. The effects of 3,4-methy-lenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphe-tamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 1986; 128: 41-48
106. Tancer M, Johanson CE. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 2007; 189: 565-573
107. Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology (Berl) 2003; 167: 85-96.
108. Tohka J, Zijdenbos A, Evans A. Fast and robust parameter estimation for statistical partial volume models in brain MRI. Neuroimage 2004; 23: 84-97.
109. Trigo JM, Renoir T, Lanfumey L, Hamon M, Lesch KP, Robledo P, et al. 3,4-methylenedioxymethamphetamine self-administration is abolished in serotonin transporter knockout mice. Biol Psychiatry 2007; 62: 669-679
110. Turkheimer FE, Brett M, Visvikis D, Cunningham VJ. Multiresolution analysis of emission tomography images in the wavelet domain. J Cereb Blood Flow Metab 1999; 19: 1189-1208
111. Verrico CD, Miller GM, Madras BK. MDMA (Ecstasy) and human dopa-mine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl) 2007; 189: 489-503.
112. Warrington EK. Manual for recognition memory test. NFER-Nelson: Windsor; 1984.
113. Wechsler D. Manual for the Wechsler Adult Intelligence Scale-Revised. New York: The Psychological Corporation; 1981.
114. 11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl Med Biol 2002; 29: 509-515
115. Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab 2002; 22: 1440-1452
116. Zijdenbos AP, Forghani R, Evans AC. Automatic "pipeline" analysis of 3D MRI data for clinical trials: application to multiple sclerosis. IEEE Trans Med Imaging 2002; 21: 1280-1291